Dexmedetomidine Use in SZMN Blocks for Pediatric T&A Pain Control
Postoperative Pain, Opioid Use
About this trial
This is an interventional treatment trial for Postoperative Pain focused on measuring Suprazygomatic maxillary nerve block, Tonsillectomy and Adenoidectomy, Regional Anesthesia, Dexmedetomidine, Pediatric
Eligibility Criteria
Inclusion Criteria:
- Ages 6 months - 18 years
- Give consent/parental consent to participate in study
- Patients undergoing tonsillectomy and adenoidectomy
Exclusion Criteria:
- Participants who do not consent or have parental consent
- Patients who require urgent/emergent intervention
- Patients who undergo additional combined surgical procedures with separate incisions (in addition to the adenotonsillectomy)
- Patients with known difficult airway, clinical hemodynamic instability, coagulopathy, chronic pain history, chronic pain medication use, and unrepaired congenital heart disease
- Patients under age 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
SZMN Treatment Group
SZMN+Dexmedetomidine Treatment Group
No Intervention: Control Group
Patients randomized into the SZMN treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic per side.
Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
Patients in this group will receive the standard of care for T&A procedures within the pediatric population.